1. Home
  2. CYAB vs GNPX Comparison

CYAB vs GNPX Comparison

Compare CYAB & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cyabra Inc. Common Stock

CYAB

Cyabra Inc. Common Stock

N/A

Current Price

$0.30

Market Cap

4.2M

Sector

N/A

ML Signal

N/A

Logo Genprex Inc.

GNPX

Genprex Inc.

HOLD

Current Price

$4.70

Market Cap

3.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CYAB
GNPX
Founded
2017
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.2M
3.9M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
CYAB
GNPX
Price
$0.30
$4.70
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
187.7K
109.2K
Earning Date
04-09-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.25
$0.14
52 Week High
$2.99
$12.97

Technical Indicators

Market Signals
Indicator
CYAB
GNPX
Relative Strength Index (RSI) 38.98 53.44
Support Level N/A $1.06
Resistance Level $0.50 $9.99
Average True Range (ATR) 0.03 0.87
MACD 0.01 -0.19
Stochastic Oscillator 46.84 48.69

Price Performance

Historical Comparison
CYAB
GNPX

About CYAB Cyabra Inc. Common Stock

Cyabra Inc is an AI-powered SaaS company that detects and analyzes online disinformation. Its platform uses machine learning to monitor social media and news data in real time, identify fake accounts and harmful narratives, and assess content authenticity and sentiment.

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).

Share on Social Networks: